Ghost Tree Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Ghost Tree Capital’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-235,000	Closed	-$3.38M	–	66
2019 Q3	$3.38M	Hold	235,000	–	–	0.86%	35
2019 Q2	$3.7M	Buy	+235,000	New	+$3.2M	0.77%	33
2019 Q1	–	Sell	-1,250,000	Closed	-$13.4M	–	49
2018 Q4	$13.4M	Buy	1,250,000 +150,000	+14%	+$1.97M	4.85%	3
2018 Q3	$16.8M	Buy	1,100,000 +440,000	+67%	+$6.4M	3.57%	8
2018 Q2	$8.09M	Sell	660,000 -290,000	-31%	-$3.64M	2.38%	15
2018 Q1	$9.08M	Buy	950,000 +450,000	+90%	+$4.85M	1.84%	16
2017 Q4	$4.51M	Buy	+500,000	New	+$3.68M	1.06%	33

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Ghost Tree Capital's DRNA Position: Q4 2019 in Review

Ghost Tree Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2019, closing a stake of 235,000 shares — an estimated $3.38M sold.

Ghost Tree Capital first reported a position in DRNA in Q4 2017 and held it in 7 quarters. The position peaked at $16.8M in Q3 2018. 169 funds tracked by Wall St. Rank hold DRNA as of Q4 2019.

Ghost Tree Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Ghost Tree Capital sold 235,000 Dicerna Pharmaceuticals, Inc. shares in Q4 2019, an estimated $3.38M.
Ghost Tree Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2017 and held it in 7 quarters.
Ghost Tree Capital's Dicerna Pharmaceuticals, Inc. position peaked at $16.8M in Q3 2018.
169 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2019.

Based on Ghost Tree Capital's 13F filing for Q4 2019, filed 14 Feb 2020.